XENE vs XOMA
XENE: A pre-commercial neuroscience biotech racing to bring azetukalner, a differentiated potassium channel opener, through Phase 3 trials for epilepsy and depression. XOMA: A lean-infrastructure royalty aggregator that generates non-dilutive capital for biotech developers in exchange for long-duration milestone and royalty rights across a diversified 120+ asset portfolio spanning oncology, rare disease, and specialty therapeutics.
Side-by-side fundamentals
| Metric | XENE | XOMA | Edge |
|---|---|---|---|
| Price as of 2026-07-30 close | $64.19 | $40.17 | |
| Market cap as of 2026-07-31 | $6.2B | $504M | |
| P/E as of 2026-07-31 | n/a | 21.00 | |
| PEG as of 2026-07-31 | -0.30 | n/a | |
| Net margin as of 2026-07-31 | -867.3% | +69.6% | XOMA higher |
| Gross margin as of 2026-07-31 | n/a | +100.0% | |
| Operating margin as of 2026-07-31 | -969.8% | +61.3% | XOMA higher |
| ROE as of 2026-07-31 | -49.2% | +32.4% | XOMA higher |
| ROA as of 2026-07-31 | -46.4% | +13.1% | XOMA higher |
| Debt / equity as of 2026-07-31 | 0.00 | 0.91 | XENE lower |
| Revenue growth (YoY) as of 2026-07-31 | -7.3% | +13.2% | XOMA higher |
| Revenue CAGR (3y) SEC XBRL | -77.8% | +105.3% | XOMA higher |
| Dividend yield as of 2026-07-31 | n/a | +0.8% | |
| Beta as of 2026-07-31 | 0.94 | 0.89 | |
| 1-year return as of 2026-07-30 close | +108.6% | +57.7% | XENE higher |
Fundamentals: market data, as of 2026-07-31. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-30.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.